An impurity of Simvastatin. Simvastatin is a lipid-lowering drug that inhibits HMG-CoA reductase. It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver.
An impurity of Simvastatin. Simvastatin is a lipid-lowering drug that inhibits HMG-CoA reductase. It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver.
An intermediate in the synthesis of Simvastatin, Simvastatin is a lipid-lowering drug that inhibits HMG-CoA reductase. It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver.
An impurity of Simvastatin. Simvastatin is a lipid-lowering drug that inhibits HMG-CoA reductase. It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver.
An impurity of Simvastatin. Simvastatin is a lipid-lowering drug that inhibits HMG-CoA reductase. It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver.
An impurity of Simvastatin. Simvastatin is a lipid-lowering drug that inhibits HMG-CoA reductase. It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver.
An impurity of Simvastatin. Simvastatin is a lipid-lowering drug that inhibits HMG-CoA reductase. It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver.
An impurity of Simvastatin. Simvastatin is a lipid-lowering drug that inhibits HMG-CoA reductase. It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver.
Simeprevir plays an important role in HCV replication. Data from phase I and II clinical trials of TMC-435350 (TMC 435350; TMC 435; TMC-435350) to date have shown that this agent is well tolerated as a once-daily oral therapy and provides potent antiviral activity in HCV genotype 1-infected subjects, with restoration of liver enzymes and no evidence of viral breakthrough.
Silychristin is a new natural product has been isolated from silymarin, the hepatoprotective extract of milk thistle (Silybum marianum) fruits. Silychristin has been shown to be an antihepatotoxic flavonolignan.
Silmitasertib is an orally bioavailable inhibitor of CK2 with potential antineoplastic activity. It inhibits proliferation in cancer cell lines overexpressing CK2. It suppresses survival and induces apoptosis of cancer stem cells including glioblastomas and acute myeloid leukemia cells.
Silydianin is an active constituent of Silybium marianum and is known the exhibit anti-inflammatory activity which regulates caspase-3 activation which affects cell membranes and acts as a free radical scavenger.
SHP099 is a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor (IC50 value 0.071 μM) that stabilizes SHP2 in an auto-inhibited conformation. SHP099 suppresses signaling through the Ras-ERK pathway and blocks the proliferation of receptor tyrosine kinase-driven human cancer cells in vitro and in vivo.
SHP099 is a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor (IC50 value 0.071 μM) that stabilizes SHP2 in an auto-inhibited conformation. SHP099 suppresses signaling through the Ras-ERK pathway and blocks the proliferation of receptor tyrosine kinase-driven human cancer cells in vitro and in vivo.
Shikonin belongs naphthoquinone isolated from Arnebia sp. It is used as an anti-inflammatory treatment in traditional chinese medicine (TCM). It inhibits chemokine receptor function and suppresses HIV-1.
SH-4-54 is a potent STAT inhibitor with KD values of 300 nM and 464 nM for STAT3 and STAT5, respectively. It potently kills glioblastoma brain cancer stem cells (BTSCs).
Setipiprant is a potent, orally available and selective CRTH2 antagonist, which is a G protein-coupled receptor for PGD2. It may be a promising target for the treatment of allergic disorders. It was well tolerated and reduced both the allergen-induced LAR and the associated AHR in allergic asthmatics at multiple oral doses. It is a drug originally developed by Actelion, but it failed to show sufficient advantages and was discontinued from further development in this application. Later it was developed as a novel treatment for baldness by Kythera.
Sesamin and sesamolin have been demonstrated to possess several bioactivities beneficial for human health. Excess generation of nitric oxide in lipopolysaccharide-stimulated rat primary microglia cells was significantly attenuated when they were pretreated with sesamin or sesamolin. The neuroprotective effect of sesamin and sesamolin was also observed in vivo using gerbils subjected to a focal cerebral ischemia induced by occlusion of the right common carotid artery and the right middle cerebral artery.
Sertaconazole nitrate is a topical broad-spectrum antifungal that is developed to provide an additional agent for the treatment of superficial cutaneous and mucosal infections.
Serdemetan, also known as JNJ-26854165, is an orally bioavailable, small-molecule HDM2 antagonist with potential antineoplastic activity. HDM2 antagonist JNJ-26854165 inhibits the binding of the HDM2-p53 complex to the proteasome, blocking the degradation of p53; p53 signaling and p53-mediated induction of tumor cell apoptosis may thus be restored. In addition to p53, degradation of other HDM2 client proteins may be inhibited. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, this oncoprotein has been implicated in cancer cell proliferation and survival.
Sephin 1 is a selective PPP1R15A inhibitor devoid of PPP1R15B and α2-adrenergic activity. In cells, Sephin 1 selectively disrupted the PPP1R15A-PP1c complex, thus prolonging eIF2α phosphorylation after stress, delaying translation recovery, and attenuated expression of stress genes such as the pro-apoptotic protein CHOP. In mice, Sephin 1 safely prevented the motor, morphological, and molecular defects of two otherwise unrelated protein-misfolding diseases.
Senicapoc, previously called as ICA 17043, is a small organic potent and selective blocker of the Gardos channel which is the calcium-activated potassium channel located on the human RBC, inhibiting the efflux of K+ through this channel.
Semapimod (INN), formerly known as CNI-1493, is a cytokine inhibitor. Semapimod is an investigational new drug which has anti-inflammatory, anti-cytokine, immunomodulatory, antiviral and antimalarial properties. Structurally, semapimod is synthetic guanylhydrazone mitogen-activated protein kinase blocker, as a potential treatment for Crohn's disease and other inflammatory conditions. Clinical trials of Semapimod started in 2001.
Selumetinib, also known as AZD6244, is an orally bioavailable small molecule with potential antineoplastic activity. Selumetinib inhibits mitogen-activated protein kinase kinases (MEK or MAPK/ERK kinases) 1 and 2, which may prevent the activation of MEK1/2-dependent effector proteins and transcription factors, and so may inhibit cellular proliferation in MEK-overexpressing tumor cells. MEK 1 and 2 are dual-specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various tumor cell types, and are drivers of diverse cellular activities, including cellular proliferation. Check for active clinical trials or closed clinical trials using this agent.
Selpercatinib is a selective RET inhibitor with antineoplastic activity. It inhibits proliferation of cancer cells containing RET mutations or gene fusions. It is indicated for the treatment of non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other thyroid cancer tumors.
Selonsertib, also known as GS-4997, is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.
Selinexor is a potent and selective inhibitor of chromosome region maintenance 1 protein/exportin 1 (CRM1/XPO1). Selinexor was studied to show in vivo anti-leukaemic efficacy against T-ALL and acute myeloid leukaemia (AML) cells.
Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Seliciclib primarily inhibits CDK2/E, CDK2/A, CDK7 and CDK9 by competing for their ATP binding sites, leading to a disruption of cell cycle progression. In addition, this agent appears to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, inhibiting RNA polymerase II-dependent transcription, which may result in the down-regulation of antiapoptotic proteins such as induced myeloid leukemia cell differentiation protein Mcl-1. CDKs, serine/threonine kinases that play an important role in cell cycle regulation, are overexpressed in various malignancies. Mcl-1 belongs to the Bcl-2 family of antiapoptotic proteins and is a protein crucial to the survival of a range of tumor cell types.
Seletalisib is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by UCB. It is an immunomodulator. Phaes I clinical trials for Plaque psoriasis, phaes II clinical trials for Sjogren's syndrome and phaes III clinical trials for Immunodeficiency disorders is on-going.
Seladelpar is a selective peroxisome proliferator-activated receptor -δ receptor agonist. Phase II clinical trials for the treatment of Hyperlipidaemia, Hyperlipoproteinaemia type IIa and Primary biliary cirrhosis were on-going.
Sedanolide is a natural phthalide compound originally isolated from seed oil of the Umbelliferae family, including celery. It is an inducer of glutathione S-transferase and inhibitor of chemically induced carcinogenesis.
Secalciferol is a metabolite of Vitamin D, a possibly anti-inflammatory steroid which is involved in bone ossification. lt mediates calcium and phosphorus homeostasis and inhibits calcium channels in osteosarcoma cells via suppressing the effects of 1α, 25-dihydroxyvitamin D3 and testosterone. lt also can decrease the abundance of p53 and Pi-induced cytochrome c translocation.
S-Deoxo Fulvestrant is a derivative of Fulvestrant, an estrogen receptor antagonist used as a medication indicated for the treatment of hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women.
